The results show 83% of patients in the combination group achieved clinical response at week 12, compared to 61% of the golimumab monotherapy group and 75% of the guselkumab group.
Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib
Investegate announcements from Galapagos NV, Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn s and Colitis Organisation (ECCO) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.